TNF and rheumatic disorder: Biological drugs acting as anti-tumor necrosis factors (TNF), inhibitors of the T- and B-cell costimulation, and inhibitors of the interleukin (IL)-6 and the IL-1 have been shown to successfully reach treatment targets (e.g., remission, low disease activity) and improve patients' quality of life for several gastrointestinal and rheumatic diseases in a number of clinical situations (Mathias et al., 2000; Dignass et al., 2010, 2012; Lichtiger et al., 2010; Braun et al., 2011; Smolen et al., 2014).